Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux–Lamy syndrome)—10‐year follow‐up of patients who previously participated in an MPS VI survey study2. Issue 8 (24th April 2014)

• Record Type: Journal Article
• Authors: Giugliani, Roberto; Lampe, Christina; Guffon, Nathalie; Ketteridge, David; Leão‐Teles, Elisa; Wraith, James E.; Jones, Simon A.; Piscia‐Nichols, Cheri; Lin, Ping; Quartel, Adrian; Harmatz, Paul
• Is Part Of: American journal of medical genetics. Volume 164:Issue 8(2014.)
• Page Start: 1953
• Page End: 1964
• Publication Date: 2014-04-24
• Subjects: Medical genetics -- Periodicals; 616.14205
• DOI: 10.1002/ajmg.a.36584
• Languages: English
• ISSNs: 1552-4825

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ajmga36584-sec-0001" sec-type="section"> <p>Mucopolysaccharidosis VI (MPS VI) is a clinically heterogeneous and progressive disorder with multiorgan manifestations caused by deficient <italic>N</italic>‐acetylgalactosamine‐4‐sulfatase activity. A cross‐sectional Survey Study in individuals (n = 121) affected with MPS VI was conducted between 2001 and 2002 to establish demographics, urinary glycosaminoglycan (GAG) levels, and clinical progression of disease. We conducted a Resurvey Study (ClinicalTrials.gov: NCT01387854) to obtain 10‐year follow‐up data, including medical histories and clinical assessments (n = 59), and survival status over 12 years (n = 117). Patients received a mean (SD) of 6.8 (2.2) years of galsulfase ERT between baseline (Survey Study) and follow‐up. ERT patients increased in height by 20.4 cm in the 4–7‐year‐old baseline age group and by 16.8 cm in the 8–12‐year‐old baseline age group. ERT patients <13 years‐old demonstrated improvement in forced vital capacity (FVC) by 68% and forced expiratory volume in 1 sec (FEV1) by 55%, and those ≥13 years‐old increased FVC by 12.8% and maintained FEV1. Patients with >200 µg/mg baseline uGAG levels increased FVC by 48% in the <13‐year‐old baseline age group and by 15% in the ≥13‐year‐old baseline age group. ERT patients who completed the 6‐min walk test demonstrated a mean (SD) increase of 65.7 (100.6) m. Cardiac outcomes did not significantly improve or worsen. Observed mortality rate among naïve patients was 50% (7/14) and 16.5% (17/103) in the ERT group (unadjusted hazard ratio, 0.24; 95% CI, 0.10–0.59). Long‐term galsulfase ERT was associated with improvements in pulmonary function and endurance, stabilized cardiac function and increased survival. © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract>